Literature DB >> 26446695

Effectiveness of multi-disciplinary rehabilitation for patients with Neuromyelitis Optica.

Yael Nechemia1, Elior Moreh2, Harold Weingarden1,3, Ayala Bloch1, Uri Givon3,4, Adi Vaknin-Dembinsky2, Isabella Schwartz2, Zeev Meiner2, Gabi Zeilig1,3.   

Abstract

INTRODUCTION: Neuromyelitis optica (NMO), previously considered a subtype of multiple sclerosis (MS), is now known to be a unique disorder associated with autoantibodies against aquaporin-4. The rehabilitation protocols for MS have been applied to NMO, without specific measures of efficacy.
PURPOSE: The evaluation of the effectiveness of an MS type inpatient rehabilitation program for patients with NMO. PATIENT AND METHODS: Retrospective chart reviews of 15 inpatients with NMO and 32 inpatients with MS. Clinical severity was assessed by the Expanded Disability Status Scale (EDSS), functional assessments were scored using the Functional Independence Measure (FIM), the Montebello Rehabilitation Factor Score (MRFS), and the Functional Ambulation Category (FAC). There was a higher percentage of women in the NMO group (87% vs 56% P = 0.003). The MS group had significantly more cognitive and communication deficits (P = 0.003 and P = 0.00001). No significant differences were found in admission FIM, EDSS and FAC scores.
RESULTS: Both groups benefitted, however at discharge, the NMO group showed greater improvement in FIM scores (NMO admission 79 ± 24, discharge 98 ± 21; MS admission 80 ± 28, discharge 89 ± 28); and lower EDSS score (NMO from 7.2 ± 1.4 to 6.3 ± 1.4; MS from 7.4 ± 1.4 to 7 ± 1.5).
CONCLUSIONS: Inpatient multidisciplinary rehabilitation programs available for the patients with MS may be successfully implemented for patients with NMO.

Entities:  

Keywords:  Body structure and functions; Expanded Disability Status Scale; Functional outcomes; Multiple sclerosis; Neuromyelitis optica; Rehabilitation

Mesh:

Year:  2016        PMID: 26446695      PMCID: PMC5073758          DOI: 10.1179/2045772315Y.0000000060

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  28 in total

1.  A secondary progressive clinical course is uncommon in neuromyelitis optica.

Authors:  D M Wingerchuk; S J Pittock; C F Lucchinetti; V A Lennon; B G Weinshenker
Journal:  Neurology       Date:  2007-02-20       Impact factor: 9.910

2.  Seronegative neuromyelitis optica: improvement following lymphocytapheresis treatment.

Authors:  E Moreh; I Gartsman; D Karussis; D Rund; N Hiller; Z Meiner
Journal:  Mult Scler       Date:  2008-05-27       Impact factor: 6.312

Review 3.  Neuromyelitis optica - Devic's syndrome, update.

Authors:  Raul N Mandler
Journal:  Autoimmun Rev       Date:  2006-03-21       Impact factor: 9.754

4.  Neuromyelitis optica in France: a multicenter study of 125 patients.

Authors:  N Collongues; R Marignier; H Zéphir; C Papeix; F Blanc; C Ritleng; M Tchikviladzé; O Outteryck; S Vukusic; M Fleury; B Fontaine; D Brassat; M Clanet; M Milh; J Pelletier; B Audoin; A Ruet; C Lebrun-Frenay; E Thouvenot; W Camu; M Debouverie; A Créange; T Moreau; P Labauge; G Castelnovo; G Edan; E Le Page; G Defer; B Barroso; O Heinzlef; O Gout; D Rodriguez; S Wiertlewski; D Laplaud; F Borgel; P Tourniaire; J Grimaud; B Brochet; P Vermersch; C Confavreux; J de Seze
Journal:  Neurology       Date:  2010-03-02       Impact factor: 9.910

5.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

6.  The natural history of secondary progressive multiple sclerosis.

Authors:  Marcus Koch; Elaine Kingwell; Peter Rieckmann; Helen Tremlett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-07-16       Impact factor: 10.154

7.  Rehabilitation of neuromyelitis optica (Devic syndrome): three case reports.

Authors:  Adam L Schreiber; Guy W Fried; Christopher S Formal; Bryan X DeSouza
Journal:  Am J Phys Med Rehabil       Date:  2008-02       Impact factor: 2.159

8.  Relapsing neuromyelitis optica: long term history and clinical predictors of death.

Authors:  P Cabre; A González-Quevedo; M Bonnan; A Saiz; S Olindo; F Graus; D Smadja; H Merle; L Thomas; J A Cabrera-Gomez
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-10       Impact factor: 10.154

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

Review 10.  Multidisciplinary rehabilitation for adults with multiple sclerosis.

Authors:  F Khan; L Turner-Stokes; L Ng; T Kilpatrick
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18
View more
  4 in total

1.  Inpatient Multidisciplinary Rehabilitation Intervention Outcomes for Neuromyelitis Optica Spectrum Disorder: A Retrospective Observational Study.

Authors:  Junko Ikeda; Yumiko Kaseda; Takanori Namba; Mitsuhiro Ochi; Miwa Hayata; Tatsuo Kohriyama
Journal:  Prog Rehabil Med       Date:  2016-11-09

2.  Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic.

Authors:  Remi A Kessler; Maureen A Mealy; Michael Levy
Journal:  Curr Treat Options Neurol       Date:  2016-01       Impact factor: 3.598

3.  Rehabilitation of neuromyelitis optica: Two CARE-compliant case reports.

Authors:  Won Bin Kim; So Young Lee; Bo Ryun Kim; Youn Ji Kim
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

Review 4.  Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.

Authors:  Andrea Salazar-Camelo; Naveen George; Hesham Abboud; Sarah M Planchon; Marcelo Matiello; Maureen A Mealy; Andrew Goodman
Journal:  J Neurol       Date:  2021-09-05       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.